T 1443/15 (Lenalidomide polymorph/CELGENE) of 05.03.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T144315.20200305
- Date of decision
- 5 March 2020
- Case number
- T 1443/15
- Petition for review of
- -
- Application number
- 04783095.5
- IPC class
- A61K 31/445C07D 401/04
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE
- Applicant name
- CELGENE CORPORATION
- Opponent name
- Generics [UK] Limited
Teva Pharmaceutical Industries Ltd. - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1) (2007)European Patent Convention Art 123(2) (2007)Rules of procedure of the Boards of Appeal Art 11 (2020)Rules of procedure of the Boards of Appeal Art 12(4) (2007)Rules of procedure of the Boards of Appeal Art 13(1) (2007)
- Keywords
- Main request - admitted (yes) - added subject-matter (no) - remitted (yes)
Late-filed objections - admitted (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution.